Oskar Hansson
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 676 publications
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
Journal: JAMA
Published: July 13, 2026
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
Journal: JAMA
Published: July 13, 2026
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.
Journal: JAMA neurology
Published: May 26, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.
Journal: medRxiv : the preprint server for health sciences
Published: May 18, 2026
The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.
Journal: Neurology
Published: May 14, 2026
Stable episodic memory and high education do not influence the rate of Alzheimer's disease pathology as measured by plasma p-tau217.
Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026
Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 06, 2026
Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 23, 2026
Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 19, 2026
Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort.
Journal: Journal of the neurological sciences
Published: March 16, 2026
Last Updated: 09/26/2026